UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue

Veracyte, Inc. (NASDAQ:VCYT) ranks among the best innovative stocks to bargain according to Wall Street analysts. On January 12, UBS reaffirmed its Buy standing for Veracyte, Inc. (NASDAQ:VCYT) alongside a terms people of $48. Analyst Lu Li retained a favorable outlook aft Veracyte’s Q4 investigating gross exceeded expectations, which the institution attributed mostly to higher mean selling prices and prior-period collections alternatively than measurement maturation successful Decipher tests.

Veracyte’s 2026 investigating gross projections exceeded thoroughfare expectations, and the institution kept its projected adjusted EBITDA borderline of 25%, up from astir 21% successful 2024, which UBS deems favorable for the stock’s outlook.

The steadfast besides noted imaginable gains from caller merchandise contributions, suggesting that the company’s existent gross projection does not afloat relationship for each maturation prospects.

Overall, Veracyte, Inc. (NASDAQ:VCYT) reported preliminary fourth-quarter 2025 gross of $138-140 million, representing a 16%-18% year-over-year summation that exceeded the statement forecast of $132 million.

Veracyte, Inc. (NASDAQ:VCYT) is simply a genomic diagnostics institution that develops tests to amended diagnosis and attraction decisions for thyroid, lung, and different cancers, arsenic good arsenic autoimmune diseases.

While we admit the imaginable of VCYT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.